Better Evidence for Selecting Transplant Fluids

NCT03829488 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

808

Enrollment

OTHER

Sponsor class

Conditions

End Stage Kidney Disease
Delayed Graft Function
Kidney Transplant; Complications

Interventions

DRUG: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
DRUG: 0.9% SODIUM CHLORIDE 9g/L injection BP

Sponsor

The University of Queensland

Collaborators

[object Object]
[object Object]
[object Object]